Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery

• Main Authors: Sepideh Mirzaei (Author), Ali Zarrabi (Author), Farid Hashemi (Author), Amirhossein Zabolian (Author), Hossein Saleki (Author), Negar Azami (Author), Soodeh Hamzehlou (Author), Mahdi Vasheghani Farahani (Author), Kiavash Hushmandi (Author), Milad Ashrafizadeh (Author), Haroon Khan (Author), Alan Prem Kumar (Author)
• Format: Book
• Published: MDPI AG, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Doxorubicin (DOX) is extensively applied in cancer therapy due to its efficacy in suppressing cancer progression and inducing apoptosis. After its discovery, this chemotherapeutic agent has been frequently used for cancer therapy, leading to chemoresistance. Due to dose-dependent toxicity, high conc...